Table 5. Performance of ConSig1 and ConSig2 in the validation sets for predicting pathological complete response.
| Validation set | ConSig | NAC | AUC | 95% CI | P value | NPV (%) | PPV (%) | OR | 95% CI | P value |
|---|---|---|---|---|---|---|---|---|---|---|
| EORTC/BIG00-01 | ConSig1 | A | 0.70 | 0.55–0.85 | 5.2×10−3 | 74 | 75 | 8.33 | 2.00–44.44 | 6.0×10−3 |
| A+T | 0.60 | 0.43–0.77 | 0.12 | 62 | 70 | 3.81 | 0.87–20.75 | 0.09 | ||
| ConSig2 | A | 0.65 | 0.50–0.80 | 2.4×10−2 | 62 | 42 | 1.15 | 0.29–4.40 | 0.83 | |
| A+T | 0.65 | 0.49–0.81 | 3.6×10−2 | 59 | 60 | 2.13 | 0.50–9.92 | 0.31 | ||
| NKI | ConSig1 | A | 0.74 | 0.61–0.87 | 1.3×10−4 | 64 | 77 | 5.95 | 1.53–29.99 | 1.6×10−2 |
| ConSig2 | A | 0.64 | 0.49–0.78 | 3.1×10−2 | 59 | 62 | 2.30 | 0.65–8.86 | 0.20 |
Abbreviations: A, anthracycline-based chemotherapy; A+T, anthracycline+taxane chemotherapy; AUC, area under the ROC curve; CI, confidence interval; ConSig, Consensus Signature; EORTC, European Organisation for Research and Treatment of Cancer; NAC, neoadjuvant chemotherapy; NKI, Netherlands Cancer Institute; NPV, negative predictive value; OR, odds ratio for lack of pathological complete response; PPV, positive predictive value; ROC, receiver-operating characteristic.